Dyadic International, Inc. (DYAI): Price and Financial Metrics

Dyadic International, Inc. (DYAI): $1.39

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add DYAI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#273 of 341

in industry

DYAI Price/Volume Stats

Current price $1.39 52-week high $2.67
Prev. close $1.39 52-week low $1.19
Day low $1.36 Volume 10,800
Day high $1.46 Avg. volume 59,554
50-day MA $1.73 Dividend yield N/A
200-day MA $1.63 Market Cap 40.64M

DYAI Stock Price Chart Interactive Chart >


Dyadic International, Inc. (DYAI) Company Bio


Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.


DYAI Latest News Stream


Event/Time News Detail
Loading, please wait...

DYAI Latest Social Stream


Loading social stream, please wait...

View Full DYAI Social Stream

Latest DYAI News From Around the Web

Below are the latest news stories about DYADIC INTERNATIONAL INC that investors may wish to consider to help them evaluate DYAI as an investment opportunity.

Dyadic Attends Investor Events in December

JUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending

Yahoo | November 30, 2023

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical Study Report available in the coming weeks JUPITER, Fla., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the grow

Yahoo | November 29, 2023

Shareholders in Dyadic International (NASDAQ:DYAI) are in the red if they invested three years ago

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...

Yahoo | November 22, 2023

Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today applauds the signing of an agreement between Dyadic’s African licens

Yahoo | November 20, 2023

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript November 8, 2023 Dyadic International, Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. Operator: Good evening, and welcome to the Dyadic International’s Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode. Following management’s prepared […]

Yahoo | November 9, 2023

Read More 'DYAI' Stories Here

DYAI Price Returns

1-mo N/A
3-mo -12.58%
6-mo -10.90%
1-year -26.65%
3-year -60.29%
5-year -72.69%
YTD -13.66%
2023 30.89%
2022 -72.79%
2021 -15.99%
2020 3.86%
2019 174.07%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!